Anaptysbio, Inc. cash flow statement ANAB

Annual Quarterly

In Q1 of fiscal 2026, the quarter ended Mar 31, 2026, Anaptysbio, Inc. used $25.9 million of cash from operations, down 142.2% from the same quarter a year earlier. It spent $17,000 on capital expenditures. Free cash flow was negative, at -$25.9 million.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Mar 31, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024	Q3 FY2024 Sep 30, 2024	Q2 FY2024 Jun 30, 2024
Operating
Depreciation and amortization	0 +33.3%	0 -11.0%	-0 +7.5%	0 +190.3%	-0 -188.3%	0 -10.4%	-0 -367.3%	0 -8.9%	0 -5.5%
Stock-based compensation	9 +40.9%	14 +55.0%	24 +27.6%	25 +199.9%	6 -18.3%	9 -9.5%	19 +129.8%	8 +4.9%	8 -10.5%
Operating cash flow	4 +104.1%	-26 -142.2%	98 +247.0%	-27 -171.1%	-40 -88.7%	-11 +71.3%	-67 -94.1%	-10 +72.3%	-21 +16.1%
Investing
Capital expenditures	0 -81.1%	0 -51.4%	0 -99.6%	0 -65.7%	0 +18.2%	0 +29.6%	0 -6.1%	0 -78.4%	0 -82.6%
Investing cash flow	248 +1207.6%	35 +135.6%	74 +178.7%	48 -18.8%	92 +3871.7%	15 -78.4%	-93 -290.0%	59 +91.3%	-2 +88.1%
Financing
Stock buybacks	64 +1215.6%	0 -100.0%	3 +642.1%	10	51	4	0	0	0 -100.0%
Financing cash flow	-103 -191.7%	1 +104.2%	-43 -256.5%	-10 -114.6%	-50 -220.5%	-29 -109.7%	28 +634.3%	71 +2418.7%	42 +410.5%
Change in cash
Net change in cash	150 +884.7%	10 +142.0%	128 +196.9%	10 -91.8%	1 -92.5%	-24 -237.9%	-133 -1470.6%	120 +1444.0%	18 +130.5%
Free cash flow	4 +104.0%	-26 -141.6%	98 +246.4%	-27 -170.3%	-40 -88.6%	-11 +71.2%	-67 -93.3%	-10 +72.4%	-21 +16.6%
Per share
Free cash flow per share	0.15 +104.1%	-0.90 -158.0%	2.91 +252.6%	-0.94 -169.1%	-1.40 -79.1%	-0.35 +74.8%	-1.91 -46.6%	-0.35 +74.6%	-0.78 +18.8%
Shareholder returns
Returned to shareholders	64	0	3	10	51	4	0	0	0
Share of free cash flow	1,456.16%	—	3.45%	—	—	—	—	—	—
Ratios
Free cash flow margin	1.90%	-101.49%	90.53%	-35.86%	-180.94%	-38.66%	-155.25%	-33.73%	-194.65%
Capital expenditures to revenue	0.03%	0.07%	0.00%	0.02%	0.18%	0.13%	0.61%	0.12%	0.30%
Stock-based compensation to revenue	3.80%	55.63%	21.98%	32.18%	27.68%	33.02%	43.24%	27.28%	68.76%
Cash conversion	—	—	1.98x	-1.81x	—	—	—	—	—

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: ANAB (Nasdaq)
Fiscal year ends: June 30
Incorporated in: DE
Headquarters: San Diego, CA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1370053
Former names: ANAPTYSBIO INC (until Jun 12, 2019); ANAPTYS BIOSCIENCES INC (until Nov 20, 2007)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.